Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells

InSug O-Sullivan, Lauren K. Ng, Don M. Martinez, Tae Sung Kim, Amla Chopra, Edward P. Cohen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Immunotherapy of squamous cell carcinoma (SCC) at an early stage of the disease increases the likelihood of success. We report a new vaccination strategy designed to prepare SCC vaccines from microgram amounts of tumor tissue, enabling the treatment of patients with minimal residual disease. The vaccine was prepared by transfer of sheared genomic DNA-fragments (25 kb) from KLN205 cells, an SCC cell line of DBA/2 mouse origin, into syngeneic bone marrow-derived mature dendritic cells (DCs). More than 90% of the transfected DCs took up DNA from the neoplasm and transferred genes were expressed as protein. The DCs expressed CD11c, CD11b, and the costimulatory molecules CD40, CD80 and CD86, characteristic of mature DCs. Syngeneic DBA/2J mice, highly susceptible to the growth of KLN205 cells, were injected intravenously (i.v.) with the transfected DCs, followed by a subcutaneous (s.c.) injection of the tumor cells. The strong immunogenic properties of the transfected cells were indicated by the finding that the survival of the tumor-bearing mice was prolonged (P<.001), relative to that of mice in various control groups. Enzyme-linked immuno spot (ELISPOT IFN-γ) assays revealed the activation of cell-mediated immunity directed toward the SCC in mice immunized with the transfected DCs. Two independent in vitro cytotoxicity assays indicated the presence of robust cell-mediated immunity directed toward the SCC in mice immunized with the transfected cells.

Original languageEnglish
Pages (from-to)825-834
Number of pages10
JournalCancer Gene Therapy
Volume12
Issue number10
DOIs
Publication statusPublished - 2005 Oct 1
Externally publishedYes

Fingerprint

Dendritic Cells
Squamous Cell Carcinoma
Immunity
DNA
Inbred DBA Mouse
Cellular Immunity
Vaccines
Enzyme-Linked Immunospot Assay
Neoplasms
Neoplasm Genes
Residual Neoplasm
Subcutaneous Injections
Immunotherapy
Vaccination
Bone Marrow
Cell Line
Control Groups
Enzymes
Growth
Proteins

Keywords

  • Dendritic cells
  • Genomic DNA
  • Immunity
  • Squamous carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells. / O-Sullivan, InSug; Ng, Lauren K.; Martinez, Don M.; Kim, Tae Sung; Chopra, Amla; Cohen, Edward P.

In: Cancer Gene Therapy, Vol. 12, No. 10, 01.10.2005, p. 825-834.

Research output: Contribution to journalArticle

O-Sullivan, InSug ; Ng, Lauren K. ; Martinez, Don M. ; Kim, Tae Sung ; Chopra, Amla ; Cohen, Edward P. / Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells. In: Cancer Gene Therapy. 2005 ; Vol. 12, No. 10. pp. 825-834.
@article{4f935ef97cb4422ab535d092bea445ec,
title = "Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells",
abstract = "Immunotherapy of squamous cell carcinoma (SCC) at an early stage of the disease increases the likelihood of success. We report a new vaccination strategy designed to prepare SCC vaccines from microgram amounts of tumor tissue, enabling the treatment of patients with minimal residual disease. The vaccine was prepared by transfer of sheared genomic DNA-fragments (25 kb) from KLN205 cells, an SCC cell line of DBA/2 mouse origin, into syngeneic bone marrow-derived mature dendritic cells (DCs). More than 90{\%} of the transfected DCs took up DNA from the neoplasm and transferred genes were expressed as protein. The DCs expressed CD11c, CD11b, and the costimulatory molecules CD40, CD80 and CD86, characteristic of mature DCs. Syngeneic DBA/2J mice, highly susceptible to the growth of KLN205 cells, were injected intravenously (i.v.) with the transfected DCs, followed by a subcutaneous (s.c.) injection of the tumor cells. The strong immunogenic properties of the transfected cells were indicated by the finding that the survival of the tumor-bearing mice was prolonged (P<.001), relative to that of mice in various control groups. Enzyme-linked immuno spot (ELISPOT IFN-γ) assays revealed the activation of cell-mediated immunity directed toward the SCC in mice immunized with the transfected DCs. Two independent in vitro cytotoxicity assays indicated the presence of robust cell-mediated immunity directed toward the SCC in mice immunized with the transfected cells.",
keywords = "Dendritic cells, Genomic DNA, Immunity, Squamous carcinoma",
author = "InSug O-Sullivan and Ng, {Lauren K.} and Martinez, {Don M.} and Kim, {Tae Sung} and Amla Chopra and Cohen, {Edward P.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1038/sj.cgt.7700847",
language = "English",
volume = "12",
pages = "825--834",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells

AU - O-Sullivan, InSug

AU - Ng, Lauren K.

AU - Martinez, Don M.

AU - Kim, Tae Sung

AU - Chopra, Amla

AU - Cohen, Edward P.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Immunotherapy of squamous cell carcinoma (SCC) at an early stage of the disease increases the likelihood of success. We report a new vaccination strategy designed to prepare SCC vaccines from microgram amounts of tumor tissue, enabling the treatment of patients with minimal residual disease. The vaccine was prepared by transfer of sheared genomic DNA-fragments (25 kb) from KLN205 cells, an SCC cell line of DBA/2 mouse origin, into syngeneic bone marrow-derived mature dendritic cells (DCs). More than 90% of the transfected DCs took up DNA from the neoplasm and transferred genes were expressed as protein. The DCs expressed CD11c, CD11b, and the costimulatory molecules CD40, CD80 and CD86, characteristic of mature DCs. Syngeneic DBA/2J mice, highly susceptible to the growth of KLN205 cells, were injected intravenously (i.v.) with the transfected DCs, followed by a subcutaneous (s.c.) injection of the tumor cells. The strong immunogenic properties of the transfected cells were indicated by the finding that the survival of the tumor-bearing mice was prolonged (P<.001), relative to that of mice in various control groups. Enzyme-linked immuno spot (ELISPOT IFN-γ) assays revealed the activation of cell-mediated immunity directed toward the SCC in mice immunized with the transfected DCs. Two independent in vitro cytotoxicity assays indicated the presence of robust cell-mediated immunity directed toward the SCC in mice immunized with the transfected cells.

AB - Immunotherapy of squamous cell carcinoma (SCC) at an early stage of the disease increases the likelihood of success. We report a new vaccination strategy designed to prepare SCC vaccines from microgram amounts of tumor tissue, enabling the treatment of patients with minimal residual disease. The vaccine was prepared by transfer of sheared genomic DNA-fragments (25 kb) from KLN205 cells, an SCC cell line of DBA/2 mouse origin, into syngeneic bone marrow-derived mature dendritic cells (DCs). More than 90% of the transfected DCs took up DNA from the neoplasm and transferred genes were expressed as protein. The DCs expressed CD11c, CD11b, and the costimulatory molecules CD40, CD80 and CD86, characteristic of mature DCs. Syngeneic DBA/2J mice, highly susceptible to the growth of KLN205 cells, were injected intravenously (i.v.) with the transfected DCs, followed by a subcutaneous (s.c.) injection of the tumor cells. The strong immunogenic properties of the transfected cells were indicated by the finding that the survival of the tumor-bearing mice was prolonged (P<.001), relative to that of mice in various control groups. Enzyme-linked immuno spot (ELISPOT IFN-γ) assays revealed the activation of cell-mediated immunity directed toward the SCC in mice immunized with the transfected DCs. Two independent in vitro cytotoxicity assays indicated the presence of robust cell-mediated immunity directed toward the SCC in mice immunized with the transfected cells.

KW - Dendritic cells

KW - Genomic DNA

KW - Immunity

KW - Squamous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=30644474832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644474832&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700847

DO - 10.1038/sj.cgt.7700847

M3 - Article

VL - 12

SP - 825

EP - 834

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 10

ER -